Atorvastatin for Reduction of 28-day Mortality in Severe and Critical COVID-19 Patients: a Randomized Controlled Trial

Overview

Journal Respir Res

Specialty Pulmonary Medicine

Date 2024 Feb 23

PMID 38389078

Authors

Naglaa Hamdi Eltahan

Neamat Hamdy Elsawy

Kholoud M Abdelaaty

Amal Salah Elhamaky

Ahmed H Hassan

Moataz Maher Emara

Affiliations

Soon will be listed here.

Abstract

Background: COVID-19 is an abnormal host response to the SARS-CoV-2 infection, which is associated with endothelial dysfunction and multi-organ failure. Atorvastatin has been proposed to reduce COVID-19 severity and mortality in chronic and de-novo users.

Methods: This randomized double-blind trial included 220 COVID-19 patients admitted to Mansoura University's isolation hospital in Egypt. One hundred and ten cases were given 40 mg of atorvastatin once daily for 28 days (group A), while 110 received a placebo (group B). All patients received treatment as per hospital protocol. The primary outcome is all-cause mortality at 28 days. We also tracked 6-month mortality, time to clinical improvement, the risk of invasive mechanical ventilation, acute kidney injury, potential adverse events, and hospital and intensive care length of stay.

Results: The 28-day all-cause mortality was 52/104 (50%) in group A vs. 54/103 (52.4%) in group B, odds ratio (OR) = 0.907 (0.526, 1.565), P = 0.727; adjusted OR = 0.773 (0.407, 1.47), P = 0.433. Six-month mortality occurred in 53/102 (52%) and 59/79 (60.8%) in group A vs. B, respectively, P = 0.208. Among hospital survivors in group A vs. group B, the median time to clinical improvement was 10 days (7-14) vs. 10 (7-15), P = 0.715; the duration of hospital stay was 10 days (7-14) vs. 10 (8-17), P = 0.378. Discontinuation was higher in group B (four vs. one), but statistically insignificant, P = 0.369.

Conclusions: In adults with severe or critical COVID-19, atorvastatin did not reduce the risk of 28-day or 6-month mortality and did not shorten the length of hospital stay or time to clinical improvement. Trial registration Clinical Trial Registry (NCT04952350) on July 1st, 2021. https://clinicaltrials.gov/ct2/show/NCT04952350.

Citing Articles

Effect of IL-6R blockade on plasma lipids and clinical outcomes among hospitalized patients with COVID-19 infection.

Mohammadi K, Sleeman M, Boyapati A, Bigdelou P, Geba G, Fazio S J Lipid Res. 2024; 65(6):100568.

PMID: 38795859 PMC: 11237931. DOI: 10.1016/j.jlr.2024.100568.

References

Hills T, Lorenzi E, Berry L, Shyamsundar M, Al-Beidh F, Annane D . Simvastatin in Critically Ill Patients with Covid-19. N Engl J Med. 2023; 389(25):2341-2354. PMC: 10755839. DOI: 10.1056/NEJMoa2309995. View

Davoodi L, Jafarpour H, Oladi Z, Zakariaei Z, Tabarestani M, Ahmadi B . Atorvastatin therapy in COVID-19 adult inpatients: A double-blind, randomized controlled trial. Int J Cardiol Heart Vasc. 2021; 36:100875. PMC: 8437805. DOI: 10.1016/j.ijcha.2021.100875. View

Shah T, McCarthy M, Nasir I, Archer H, Ragheb E, Kluger J . Colchicine and high-intensity rosuvastatin in the treatment of non-critically ill patients hospitalised with COVID-19: a randomised clinical trial. BMJ Open. 2023; 13(2):e067910. PMC: 9971831. DOI: 10.1136/bmjopen-2022-067910. View

Rodrigues-Diez R, Tejera-Munoz A, Marquez-Exposito L, Rayego-Mateos S, Santos Sanchez L, Marchant V . Statins: Could an old friend help in the fight against COVID-19?. Br J Pharmacol. 2020; 177(21):4873-4886. PMC: 7323198. DOI: 10.1111/bph.15166. View

Lee K, Sewa D, Phua G . Potential role of statins in COVID-19. Int J Infect Dis. 2020; 96:615-617. PMC: 7265877. DOI: 10.1016/j.ijid.2020.05.115. View

Lavrentieva A, Kaimakamis E, Voutsas V, Bitzani M . An observational study on factors associated with ICU mortality in Covid-19 patients and critical review of the literature. Sci Rep. 2023; 13(1):7804. PMC: 10182846. DOI: 10.1038/s41598-023-34613-x. View

. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infect Dis. 2020; 20(8):e192-e197. PMC: 7292605. DOI: 10.1016/S1473-3099(20)30483-7. View

Emara M, Elsawy N, Abdelaaty K, Elhamaky A, Eltahan N . Atorvastatin for reduction of 28-day mortality in hospitalized COVID-19 patients: study protocol for a randomized, double-blinded, placebo-controlled, clinical trial. Trials. 2022; 23(1):636. PMC: 9360729. DOI: 10.1186/s13063-022-06619-9. View

Haji Aghajani M, Moradi O, Tehrani H, Amini H, Pourheidar E, Hatami F . Promising effects of atorvastatin on mortality and need for mechanical ventilation in patients with severe COVID-19; a retrospective cohort study. Int J Clin Pract. 2021; 75(9):e14434. PMC: 8237071. DOI: 10.1111/ijcp.14434. View

10.

Bifulco M, Gazzerro P . Statin therapy in COVID-19 infection: much more than a single pathway. Eur Heart J Cardiovasc Pharmacother. 2020; 6(6):410-411. PMC: 7314101. DOI: 10.1093/ehjcvp/pvaa055. View

11.

Sun J, Liu Y, Zou L, Zhang W, Li J, Wang Y . Acute gastrointestinal injury in critically ill patients with COVID-19 in Wuhan, China. World J Gastroenterol. 2020; 26(39):6087-6097. PMC: 7584062. DOI: 10.3748/wjg.v26.i39.6087. View

12.

Rodriguez-Nava G, Trelles-Garcia D, Yanez-Bello M, Chung C, Trelles-Garcia V, Friedman H . Atorvastatin associated with decreased hazard for death in COVID-19 patients admitted to an ICU: a retrospective cohort study. Crit Care. 2020; 24(1):429. PMC: 7358561. DOI: 10.1186/s13054-020-03154-4. View

13.

Talasaz A, Sadeghipour P, Aghakouchakzadeh M, Dreyfus I, Kakavand H, Ariannejad H . Investigating Lipid-Modulating Agents for Prevention or Treatment of COVID-19: JACC State-of-the-Art Review. J Am Coll Cardiol. 2021; 78(16):1635-1654. PMC: 8504484. DOI: 10.1016/j.jacc.2021.08.021. View

14.

Ragab D, Salah Eldin H, Taeimah M, Khattab R, Salem R . The COVID-19 Cytokine Storm; What We Know So Far. Front Immunol. 2020; 11:1446. PMC: 7308649. DOI: 10.3389/fimmu.2020.01446. View

15.

Lang T, Altman D . Basic statistical reporting for articles published in biomedical journals: the "Statistical Analyses and Methods in the Published Literature" or the SAMPL Guidelines. Int J Nurs Stud. 2014; 52(1):5-9. DOI: 10.1016/j.ijnurstu.2014.09.006. View

16.

Ghati N, Bhatnagar S, Mahendran M, Thakur A, Prasad K, Kumar D . Statin and aspirin as adjuvant therapy in hospitalised patients with SARS-CoV-2 infection: a randomised clinical trial (RESIST trial). BMC Infect Dis. 2022; 22(1):606. PMC: 9270743. DOI: 10.1186/s12879-022-07570-5. View

17.

Kellum J, Lameire N . Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1). Crit Care. 2013; 17(1):204. PMC: 4057151. DOI: 10.1186/cc11454. View

18.

Ghafoori M, Saadati H, Taghavi M, Azimian A, Alesheikh P, Mohajerzadeh M . Survival of the hospitalized patients with COVID-19 receiving atorvastatin: A randomized clinical trial. J Med Virol. 2022; 94(7):3160-3168. PMC: 9088596. DOI: 10.1002/jmv.27710. View

19.

Hojyo S, Uchida M, Tanaka K, Hasebe R, Tanaka Y, Murakami M . How COVID-19 induces cytokine storm with high mortality. Inflamm Regen. 2020; 40:37. PMC: 7527296. DOI: 10.1186/s41232-020-00146-3. View

20.

Bouillon K, Baricault B, Semenzato L, Botton J, Bertrand M, Drouin J . Association of Statins for Primary Prevention of Cardiovascular Diseases With Hospitalization for COVID-19: A Nationwide Matched Population-Based Cohort Study. J Am Heart Assoc. 2022; 11(12):e023357. PMC: 9238639. DOI: 10.1161/JAHA.121.023357. View